OverviewSuggest Edit

Alector is a clinical-stage biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. It offers AL001, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.

TypePublic
Founded2013
HQSouth San Francisco, CA, US
Websitealector.com

Latest Updates

Employees (est.) (Mar 2020)126(+5%)
Job Openings19
Revenue (FY, 2020)$21.1 M
Share Price (Jun 2021)$19.5
Cybersecurity ratingBMore

Key People/Management at Alector

Arnon Rosenthal

Arnon Rosenthal

Chief Executive Officer, Co-Founder and Director
Shehnaaz Suliman

Shehnaaz Suliman

President and Chief Operating Officer
Robert King

Robert King

Chief Development Officer
Sabah Oney

Sabah Oney

Chief Business Officer
Robert Paul

Robert Paul

Chief Medical Officer
Calvin yu

Calvin yu

VP, Finance
Show more

Alector Office Locations

Alector has offices in South San Francisco and Milpitas
South San Francisco, CA, US (HQ)
131 Oyster Point Blvd #600
Milpitas, CA, US
521 Cottonwood Dr #112
Show all (2)

Alector Financials and Metrics

Alector Revenue

Alector's revenue was reported to be $21.1 m in FY, 2020
USD

Revenue (FY, 2020)

21.1m

Net income (FY, 2020)

(190.2m)

EBIT (FY, 2020)

(195.2m)

Market capitalization (4-Jun-2021)

1.6b

Closing stock price (4-Jun-2021)

19.5

Cash (31-Dec-2020)

50.0m

EV

1.6b
Alector's current market capitalization is $1.6 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.7m27.7m21.2m21.1m

Revenue growth, %

798%641%(23%)

General and administrative expense

6.5m11.9m35.1m59.4m

R&D expense

29.9m73.0m100.5m156.9m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

4.8m7.1m2.7m5.6m6.9m2.7m7.2m3.2m

General and administrative expense

2.4m2.5m8.3m5.8m8.4m8.3m14.6m15.7m

R&D expense

11.7m16.8m28.5m20.6m25.6m28.5m34.6m34.1m

Operating expense total

14.1m19.3m36.8m26.4m34.1m36.8m49.2m49.8m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

32.5m65.5m89.6m50.0m

Accounts Receivable

238.0k

Prepaid Expenses

285.0k2.8m4.4m8.2m

Current Assets

233.0m293.2m357.4m421.5m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

41.9m61.0m69.2m87.0m160.9m92.5m

Prepaid Expenses

3.9m5.5m3.7m4.0m7.7m6.4m

Current Assets

312.6m442.1m414.6m385.5m556.2m510.1m

PP&E

3.6m21.7m32.0m33.9m32.7m31.5m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(32.5m)(52.2m)(105.4m)(190.2m)

Depreciation and Amortization

680.0k1.0m3.8m5.9m

Accounts Payable

(41.0k)(809.0k)152.0k2.4m

Cash From Operating Activities

(17.8m)127.5m(99.3m)(166.7m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(8.4m)(19.6m)(34.9m)(18.6m)(43.1m)(74.9m)(40.0m)(85.3m)

Depreciation and Amortization

212.0k464.0k743.0k298.0k1.1m2.4m1.4m2.9m

Accounts Payable

(783.0k)(830.0k)(604.0k)683.0k414.0k132.0k3.1m4.4m

Cash From Operating Activities

184.5m167.5m145.1m(23.6m)(41.6m)(70.5m)(32.3m)(78.3m)
USDFY, 2017

Financial Leverage

-4.5 x
Show all financial metrics

Alector Operating Metrics

FY, 2018FY, 2019

Immune System Targets Identified to Date

120

Patent Applications

100190

Patent Families

2530

Product Candidates

4
Show all operating metrics

Alector Acquisitions / Subsidiaries

Company NameDateDeal Size
Alector LLC

Alector Revenue Breakdown

Embed Graph

Alector revenue breakdown by business segment: 100.0% from Collaboration

Alector Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Alector Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Alector Online and Social Media Presence

Embed Graph

Alector News and Updates

Alector to Present at Upcoming Virtual Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside…

Alector Reports 2021 First Quarter Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced business updates and financial results for the first quarter ended March 31, 2021.

Alector to Present at Stifel’s 3rd Annual CNS Day

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fires…

Thinking about buying stock in PLBY Group, Livexlive Media, Alector, Pixelworks, or Frequency Therapeutics?

NEW YORK, March 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLBY, LIVX, ALEC, PXLW, and FREQ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL0…

Alector Announces Departure of Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business officer (CBO), Sabah Oney, Ph.D., will be leaving the Company to pursue other opportunities. Shehnaaz…
Show more

Alector Frequently Asked Questions

  • When was Alector founded?

    Alector was founded in 2013.

  • Who are Alector key executives?

    Alector's key executives are Arnon Rosenthal, Shehnaaz Suliman and Robert King.

  • How many employees does Alector have?

    Alector has 126 employees.

  • What is Alector revenue?

    Latest Alector annual revenue is $21.1 m.

  • What is Alector revenue per employee?

    Latest Alector revenue per employee is $167.4 k.

  • Who are Alector competitors?

    Competitors of Alector include ACADIA Pharmaceuticals, Verge Genomics and Encoded Therapeutics.

  • Where is Alector headquarters?

    Alector headquarters is located at 131 Oyster Point Blvd #600, South San Francisco.

  • Where are Alector offices?

    Alector has offices in South San Francisco and Milpitas.

  • How many offices does Alector have?

    Alector has 2 offices.